Title:
Dexmedetomidine as an antiepileptic in super refractory status epilepticus

dc.contributor.authorBikram Kumar Gupta
dc.contributor.authorArun Raj Pandey
dc.contributor.authorShardendu Singh
dc.contributor.authorMadhup Kumar Singh
dc.date.accessioned2026-02-07T09:09:38Z
dc.date.issued2019
dc.description.abstractRefractory and super-refractory status epilepticus (SRSE) is a life-threatening neurological emergency, associated with very high morbidity and mortality. Treatment should be aimed to stop seizure and to avoid cerebral damage and morbidity related to it. The term SRSE is reserved for the patients who continue to have seizures despite the use of general anesthetic agents, or for whom seizures recur when therapy is tapered or withdrawn. A variety of treatment modalities are present, almost entirely based upon open observational studies or case reports. Therapy includes anesthesia, antiepileptic drug therapy, hypothermia, ketogenic diet, other medical, immunological, and physical therapies. In our case the patient’s seizure subsided after starting dexmedetomidine infusion while other antiepileptics had been completely stopped except valproic acid. © 2019 Faculty of Anaesthesia, Pain and Intensive Care, AFMS. All rights reserved.
dc.identifier.issn16078322
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/34544
dc.publisherFaculty of Anaesthesia, Pain and Intensive Care, AFMS
dc.subjectDexmedetomidine
dc.subjectNeurocritical care
dc.subjectStatus epilepticus
dc.subjectSuper refractory status epilepticus
dc.titleDexmedetomidine as an antiepileptic in super refractory status epilepticus
dc.typePublication
dspace.entity.typeArticle

Files

Collections